Clinical Trial Update: Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase I trial update evaluating SIM0270 alone and in combination for ER-positive, HER2-negative locally advanced or metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SIM0270 (SIM0270)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING